Chemosensitivity testing--present and future in Japan.

Tetsuro Kubota, Yoshihide Otani, Toshiharu Furukawa, Hirotoshi Hasegawa, Masahiko Watanabe, Masaki Kitajima

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Radical surgery with extended lymph node dissection is the first and only curative treatment of gastrointestinal cancer. Although the combined cancer chemotherapy has achieved 30%-50% response rates, a controversy still remains over the significance of the adjuvant cancer chemotherapy after surgery. To break through this limitation, we have introduced the chemosensitivity test to evaluate the appropriate adjuvant cancer chemotherapy for advanced gastrointestinal cancer. Our plural studies indicated that the chemosensitivity test would be useful in evaluating the appropriated adjuvant chemotherapy by increasing survival in the sensitive group. Recently, the molecular targets have been clarified for the conventionally available antitumor agents, e.g., thymidylate synthetase for 5-fluorouracil, ATP-binding cassette transporters for anthracyclines, glutathione-related detoxification for platins, and topoisomerase I for CPT-11, which will be applied for dinical use in evaluating the appropriate cancer chemotherapy. The chemosensitivity test is approved as "advanced clinical medicine" by the Japanese Ministry of Health, Welfare, and Labor in five institutes at present. Because complete dissection and chemosensitivity test-guided adjuvant chemotherapy will result in a survival benefit for patients with advanced gastrointestinal cancer, this test should be approved as "social insurance" for further wide clinical application.

Original languageEnglish
Pages (from-to)231-241
Number of pages11
JournalRecent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
Volume161
Publication statusPublished - 2003

Fingerprint

Adjuvant Chemotherapy
Gastrointestinal Neoplasms
Japan
irinotecan
Neoplasms
Drug Therapy
Thymidylate Synthase
Type I DNA Topoisomerase
ATP-Binding Cassette Transporters
Survival
Social Security
Anthracyclines
Clinical Medicine
Dizziness
Lymph Node Excision
Fluorouracil
Antineoplastic Agents
Glutathione
Dissection
Health

Cite this

Chemosensitivity testing--present and future in Japan. / Kubota, Tetsuro; Otani, Yoshihide; Furukawa, Toshiharu; Hasegawa, Hirotoshi; Watanabe, Masahiko; Kitajima, Masaki.

In: Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer, Vol. 161, 2003, p. 231-241.

Research output: Contribution to journalArticle

Kubota, Tetsuro ; Otani, Yoshihide ; Furukawa, Toshiharu ; Hasegawa, Hirotoshi ; Watanabe, Masahiko ; Kitajima, Masaki. / Chemosensitivity testing--present and future in Japan. In: Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer. 2003 ; Vol. 161. pp. 231-241.
@article{3508b3cc4eae462d8e50521d7f5eb738,
title = "Chemosensitivity testing--present and future in Japan.",
abstract = "Radical surgery with extended lymph node dissection is the first and only curative treatment of gastrointestinal cancer. Although the combined cancer chemotherapy has achieved 30{\%}-50{\%} response rates, a controversy still remains over the significance of the adjuvant cancer chemotherapy after surgery. To break through this limitation, we have introduced the chemosensitivity test to evaluate the appropriate adjuvant cancer chemotherapy for advanced gastrointestinal cancer. Our plural studies indicated that the chemosensitivity test would be useful in evaluating the appropriated adjuvant chemotherapy by increasing survival in the sensitive group. Recently, the molecular targets have been clarified for the conventionally available antitumor agents, e.g., thymidylate synthetase for 5-fluorouracil, ATP-binding cassette transporters for anthracyclines, glutathione-related detoxification for platins, and topoisomerase I for CPT-11, which will be applied for dinical use in evaluating the appropriate cancer chemotherapy. The chemosensitivity test is approved as {"}advanced clinical medicine{"} by the Japanese Ministry of Health, Welfare, and Labor in five institutes at present. Because complete dissection and chemosensitivity test-guided adjuvant chemotherapy will result in a survival benefit for patients with advanced gastrointestinal cancer, this test should be approved as {"}social insurance{"} for further wide clinical application.",
author = "Tetsuro Kubota and Yoshihide Otani and Toshiharu Furukawa and Hirotoshi Hasegawa and Masahiko Watanabe and Masaki Kitajima",
year = "2003",
language = "English",
volume = "161",
pages = "231--241",
journal = "Recent Results in Cancer Research",
issn = "0080-0015",
publisher = "Springer New York",

}

TY - JOUR

T1 - Chemosensitivity testing--present and future in Japan.

AU - Kubota, Tetsuro

AU - Otani, Yoshihide

AU - Furukawa, Toshiharu

AU - Hasegawa, Hirotoshi

AU - Watanabe, Masahiko

AU - Kitajima, Masaki

PY - 2003

Y1 - 2003

N2 - Radical surgery with extended lymph node dissection is the first and only curative treatment of gastrointestinal cancer. Although the combined cancer chemotherapy has achieved 30%-50% response rates, a controversy still remains over the significance of the adjuvant cancer chemotherapy after surgery. To break through this limitation, we have introduced the chemosensitivity test to evaluate the appropriate adjuvant cancer chemotherapy for advanced gastrointestinal cancer. Our plural studies indicated that the chemosensitivity test would be useful in evaluating the appropriated adjuvant chemotherapy by increasing survival in the sensitive group. Recently, the molecular targets have been clarified for the conventionally available antitumor agents, e.g., thymidylate synthetase for 5-fluorouracil, ATP-binding cassette transporters for anthracyclines, glutathione-related detoxification for platins, and topoisomerase I for CPT-11, which will be applied for dinical use in evaluating the appropriate cancer chemotherapy. The chemosensitivity test is approved as "advanced clinical medicine" by the Japanese Ministry of Health, Welfare, and Labor in five institutes at present. Because complete dissection and chemosensitivity test-guided adjuvant chemotherapy will result in a survival benefit for patients with advanced gastrointestinal cancer, this test should be approved as "social insurance" for further wide clinical application.

AB - Radical surgery with extended lymph node dissection is the first and only curative treatment of gastrointestinal cancer. Although the combined cancer chemotherapy has achieved 30%-50% response rates, a controversy still remains over the significance of the adjuvant cancer chemotherapy after surgery. To break through this limitation, we have introduced the chemosensitivity test to evaluate the appropriate adjuvant cancer chemotherapy for advanced gastrointestinal cancer. Our plural studies indicated that the chemosensitivity test would be useful in evaluating the appropriated adjuvant chemotherapy by increasing survival in the sensitive group. Recently, the molecular targets have been clarified for the conventionally available antitumor agents, e.g., thymidylate synthetase for 5-fluorouracil, ATP-binding cassette transporters for anthracyclines, glutathione-related detoxification for platins, and topoisomerase I for CPT-11, which will be applied for dinical use in evaluating the appropriate cancer chemotherapy. The chemosensitivity test is approved as "advanced clinical medicine" by the Japanese Ministry of Health, Welfare, and Labor in five institutes at present. Because complete dissection and chemosensitivity test-guided adjuvant chemotherapy will result in a survival benefit for patients with advanced gastrointestinal cancer, this test should be approved as "social insurance" for further wide clinical application.

UR - http://www.scopus.com/inward/record.url?scp=0038005521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038005521&partnerID=8YFLogxK

M3 - Article

VL - 161

SP - 231

EP - 241

JO - Recent Results in Cancer Research

JF - Recent Results in Cancer Research

SN - 0080-0015

ER -